Thorlab-Therapeutic Oligodeoxynucleotide Research Laboratory, Department of Molecular Biology and Genetics, Faculty of Science, Ihsan Dogramaci Bilkent University, Ankara, Turkey.
Immune Modulation Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Int Immunol. 2020 Jan 9;32(1):39-48. doi: 10.1093/intimm/dxz059.
Immune-mediated inflammation must be down-regulated to facilitate tissue remodeling during homeostatic restoration of an inflammatory response. Uncontrolled or over-exuberant immune activation can cause autoimmune diseases, as well as tissue destruction. A151, the archetypal example of a chemically synthesized suppressive oligodeoxynucleotide (ODN) based on repetitive telomere-derived TTAGGG sequences, was shown to successfully down-regulate a variety of immune responses. However, the degree, duration and breadth of A151-induced transcriptome alterations remain elusive. Here, we performed a comprehensive microarray analysis in combination with Ingenuity Pathway Analysis (IPA) using murine splenocytes to investigate the underlying mechanism of A151-dependent immune suppression. Our results revealed that A151 significantly down-regulates critical mammalian target of rapamycin (mTOR) activators (Pi3kcd, Pdpk1 and Rheb), elements downstream of mTOR signaling (Rps6ka1, Myc, Stat3 and Slc2a1), an important component of the mTORC2 protein complex (Rictor) and Mtor itself. The effects of A151 on mTOR signaling were dose- and time-dependent. Moreover, flow cytometry and immunoblotting analyses demonstrated that A151 is able to reverse mTOR phosphorylation comparably to the well-known mTOR inhibitor rapamycin. Furthermore, Seahorse metabolic assays showed an A151 ODN-induced decrease in both oxygen consumption and glycolysis implying that a metabolically inert state in macrophages could be triggered by A151 treatment. Overall, our findings suggested novel insights into the mechanism by which the immune system is metabolically modulated by A151 ODN.
在炎症反应的稳态恢复过程中,必须下调免疫介导的炎症,以促进组织重塑。不受控制或过度旺盛的免疫激活会导致自身免疫性疾病和组织破坏。A151 是基于重复端粒衍生的 TTAGGG 序列的化学合成抑制性寡脱氧核苷酸 (ODN) 的典型范例,已被证明可成功下调多种免疫反应。然而,A151 诱导的转录组改变的程度、持续时间和广度仍不清楚。在这里,我们使用小鼠脾细胞进行了全面的微阵列分析,并结合了 Ingenuity 通路分析 (IPA),以研究 A151 依赖性免疫抑制的潜在机制。我们的结果表明,A151 可显著下调关键的哺乳动物雷帕霉素靶蛋白 (mTOR) 激活剂 (Pi3kcd、Pdpk1 和 Rheb)、mTOR 信号下游元件 (Rps6ka1、Myc、Stat3 和 Slc2a1)、mTORC2 蛋白复合物的重要组成部分 (Rictor) 和 mTor 本身。A151 对 mTOR 信号的影响具有剂量和时间依赖性。此外,流式细胞术和免疫印迹分析表明,A151 能够逆转 mTOR 磷酸化,与著名的 mTOR 抑制剂雷帕霉素相当。此外, Seahorse 代谢测定表明,A151 ODN 诱导的耗氧量和糖酵解均降低,这意味着 A151 处理可引发巨噬细胞中的代谢惰性状态。总的来说,我们的研究结果为 A151 ODN 调节免疫系统代谢的机制提供了新的见解。